Apellis (APLS) is down -24.8%, or -$7.46 to $22.59.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Midday Fly By: Big Tech reports, Novo tops Pfizer bid for Metsera
- Apellis falls -19.3%
- Buy Rating for Apellis Pharmaceuticals Driven by Strong Financial Performance and Promising Product Developments
- Positive Outlook for Apellis Pharmaceuticals: Strong Performance and Strategic Positioning Support Buy Rating
- Apellis reports Q3 EPS $1.71, consensus 94c